Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session on Gastrointestinal tumours 1

119MO - Application of an artificial neural network for predicting the chemotherapy benefit of patients with gastric cancer after radical surgery

Date

20 Nov 2020

Session

Mini oral session on Gastrointestinal tumours 1

Topics

Cytotoxic Therapy;  Surgical Oncology

Tumour Site

Gastric Cancer

Presenters

Zhen Xue

Citation

Annals of Oncology (2020) 31 (suppl_6): S1287-S1318. 10.1016/annonc/annonc356

Authors

Z. Xue, D. Wu, L. Shen, J. Lu, C. Zheng, P. Li, J. Xie, J. Wang, J. Lin, Q. Chen, L. Cao, M. Lin, R. Tu, Z. Huang, J. Lin, H. Zheng, C. Huang

Author affiliations

  • Department Of Gastric Surgery, Fujian Medical University Union Hospital, 350001 - Fuzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 119MO

Background

Artificial neural network (ANN) models have a strong self-learning ability and can deal with complex biological information, but there is no ANN model for predicting the benefits of adjuvant chemotherapy in patients with gastric cancer (GC).

Methods

The clinicopathological data of patients who underwent radical resection of GC from January 2010 to September 2014 were analyzed retrospectively. Patients who underwent surgery combined with adjuvant chemotherapy were randomly divided into a training cohort (70%) and a validation cohort (30%). An ANN model (CT-benefit-ANN) was established, and its ability to predict the benefit of chemotherapy was evaluated by the C-index. The prognostic prediction and stratification ability of CT-benefit-ANN and the 8th AJCC staging system were compared by ROC curves and Kaplan-Meier curves.

Results

In the training and validation cohort, CT-benefit-ANN both shows good prediction accuracy for adjuvant chemotherapy benefit. The ROC curve showed that the prediction accuracy of CT-benefit-ANN was better than that of the 8th AJCC staging system in all groups. The calibration plots showed that the predicted prognosis of CT-benefit-ANN was highly consistent with the actual value. The survival curves showed that CT-benefit-ANN could stratify prognosis well for all groups and performed significantly better than the 8th AJCC staging system.

Conclusions

The CT-benefit-ANN model developed in this study can accurately predict the benefits of adjuvant chemotherapy in patients with stage II/III GC. The benefit score based on CT-benefit-ANN can predict the long-term prognosis of patients with adjuvant chemotherapy and has good prognostic stratification ability.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Scientific and Technological Innovation Joint Capital Projects of Fujian Province.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.